What is William Blair's Forecast for IRTC Q4 Earnings?

iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) - Stock analysts at William Blair issued their Q4 2026 earnings per share (EPS) estimates for shares of iRhythm Technologies in a research note issued on Friday, May 2nd. William Blair analyst M. Andrew anticipates that the company will post earnings per share of $0.27 for the quarter. The consensus estimate for iRhythm Technologies' current full-year earnings is ($1.98) per share.

IRTC has been the subject of several other reports. Truist Financial upped their target price on iRhythm Technologies from $111.00 to $145.00 and gave the company a "buy" rating in a report on Friday, February 21st. Robert W. Baird raised their target price on iRhythm Technologies from $133.00 to $150.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Oppenheimer raised their price objective on shares of iRhythm Technologies from $105.00 to $120.00 and gave the stock an "outperform" rating in a report on Wednesday, January 8th. StockNews.com lowered iRhythm Technologies from a "hold" rating to a "sell" rating in a report on Monday. Finally, The Goldman Sachs Group increased their target price on shares of iRhythm Technologies from $91.00 to $124.00 and gave the stock a "neutral" rating in a research report on Monday, February 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, iRhythm Technologies presently has a consensus rating of "Moderate Buy" and a consensus price target of $128.55.

iRhythm Technologies Stock Up 0.8 %

IRTC stock traded up $1.11 during trading on Monday, reaching $136.29. The stock had a trading volume of 612,591 shares, compared to its average volume of 468,458. The company has a quick ratio of 6.12, a current ratio of 6.27 and a debt-to-equity ratio of 9.00. The company has a market capitalization of $4.35 billion, a price-to-earnings ratio of -37.44 and a beta of 1.34. iRhythm Technologies has a one year low of $55.92 and a one year high of $138.88. The company's 50 day moving average is $105.22 and its two-hundred day moving average is $97.68.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.06). The firm had revenue of $158.68 million for the quarter, compared to analysts' expectations of $153.39 million. iRhythm Technologies had a negative return on equity of 118.83% and a negative net margin of 19.14%. iRhythm Technologies's revenue was up 20.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.23) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. MCF Advisors LLC purchased a new position in iRhythm Technologies during the first quarter worth about $25,000. R Squared Ltd purchased a new position in shares of iRhythm Technologies during the fourth quarter worth about $45,000. Van ECK Associates Corp increased its position in shares of iRhythm Technologies by 41.3% in the fourth quarter. Van ECK Associates Corp now owns 554 shares of the company's stock worth $50,000 after purchasing an additional 162 shares during the last quarter. CWM LLC raised its stake in iRhythm Technologies by 54.3% in the first quarter. CWM LLC now owns 517 shares of the company's stock valued at $54,000 after purchasing an additional 182 shares in the last quarter. Finally, Raiffeisen Bank International AG purchased a new stake in iRhythm Technologies in the fourth quarter valued at approximately $60,000.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.